PUBLISHABLE RESULTS COVERING THE WHOLE DURATION OF BIOCARE

WP 1

1) Crespo P, Shakirin G, Enghardt W (2006). On the detector arrangement for in-beam PET for hadron therapy monitoring. *Phys Med Biol* 51(9):2143-2163.

2) Meyer TC, Powolny F, Anghinolf, F, Auffray E, Dosanjh M, Hillemanns H, Hoffmann H-F, Jarron P, Kaplon J, Kronberger M, Lecoq P, Moraes D, Trummer J (2006**).** A time-based front end readout system for PET & CT. *IEEE Nuclear Science Symposium and Medical Imaging Conference,* San Diego, October 2006 *IEEE Conf Record* 4:2494-2498.

3) Moszyński M, Kapusta M, Nassalski A, Szczęśniak T, Wolski, D, Eriksson L, Melcher CL (2006). New prospects for time-of-flight PET with LSO scintillators. *IEEE Trans Nucl Sci* 53(5):2484-2488.

4) Müller H, Enghardt W (2006). In-beam PET at high-energy photon beams: a feasibility study. *Phys. Med. Biol.* 51(7):1779-1789.

5) Robson C, Bousselham A, Bohm C (2006). An FPGA based general purpose data acquisition controller. *IEEE Trans Nucl Sci* 53(4):2092-2096.

6) Moszyński M, Gierlik, M. Kapusta, A. Nassalski, Szczęśniak T, Fontaine CH, Lavoute P (2006). New Photonis XP20D0 photomultiplier for fast timing in nuclear medicine. *Nucl Instr Meth* A567:31-35.

7) Bousselham A (2007). FPGA based data acquisition and digital pulse processing for PET and SPECT. *Doctoral Thesis*, Stockholm University, Stockholm, Sweden.

8) Bousselham A, Bohm C (2007). Sampling pulses for optimal timing. *IEEE Trans Nucl Sci.* 54(2):320-326.

9) Kluge T (2007). In-beam Positronen-Emissions-Tomografie an Strahlen harter Photonen. *Diploma Thesis*, Technische Universität Dresden.

10) Möckel D, Müller H, Pawelke J, Sommer M, Will E, Enghardt W (2007). Quantification of β^+ activity generated by hard photons by means of PET. *Phys Med Biol* 52(9):2515-2530.

11) Nassalski A, Kapusta M, Batsch T, Wolski D, Möckel D, Enghardt W, Moszyński M (2007). Comparative study of scintillators for PET/CT detectors. *IEEE Trans Nucl Sci* 54(1):3-10.

12) Möckel D, Kluge T, Pawelke J, Enghardt W (2007). Results of first experiments on in beam PET at 34 MV bremsstrahlung beams. FZ Dresden-Rossendorf, Institute of Radiation Physics, *Annual Report* 2006.

13) Kluge T, Möckel D, Pawelke J, Enghardt W (2007). First in-beam PET measurement of β^+ radioactivi-ty induced by hard photon beams. *Phys Med Biol* 52:467-N473.

14) Nassalski A, Moszyński M, Szczęśniak T, Wolski D, Batsch T (2007). The road to the common PET/CT detector. *IEEE Trans Nucl Sci* 54(5):1459-1463.

15) Würschig T, Kluge T, Heidel K, Sobiella M, Enghardt W (2007). An experimental positron emission tomography for education. *Z Med Phys* 17(3):212-217.

16) Szczęśniak T, Moszyński M., Nassalski A, Lavoute P, Dehaine AG (2007). A further study of timing with LSO on XP20D0 for TOF PET. *IEEE Nuclear Science Symposium*

and Medical Imaging Conference, San Diego, October 2006, *IEEE Trans Nucl Sci* 54(5):1464-1473.

17) Nassalski A, Moszyński M, Syntfeld-Każuch A, Świderski Ł, Szczęśniak T, Wolski D, Batsch T (2008). Application of Hamamatsu S8550APD array to the common PET/CT detector. *IEEE Nuclear Science Symposium and Medical Imaging Conference*, Honolulu, October 2007, *IEEE Trans Nucl Sci* 55(5):2460-2464.

18) Fiedler F, Priegnitz M, Jülich R, Pawelke J, Crespo P, Parodi K, Pönisch F, Enghardt W (2008). In-beam PET measurements of biological half-lives of ^{12}C irradiation induced β^+-activity. *Acta Oncol* 47(6):1077-1086.

19) Powolny P, Auffray E, Hillermanns H, Jarron P, Lecoq P, Meyer TC, Moraes D (2008). A novel time-based readout scheme for a combined PET-CT detector using APDs. *IEEE TransNucl Sci* 55(5):2465-2474.

20) Szczęśniak T, Moszyński M, Świderski Ł, Nassalski A, Lavoute P, Kapusta M (2009). Fast photomultipliers for TOF PET. *IEEE Trans Nucl Sci* 56(1):173-181.

21) Kunath D, Kluge T, Priegnitz M, Pawelke J, Enghardt W (2009). In-beam and off-beam PET measurements of target activation by Megavolt X-ray beams. *IEEE Trans Nucl Sci* 56(1):57-65.

22) Szczęśniak T, Moszyński M, Świderski Ł, Nassalski A, Syntfeld-Każuch A, Dehaine AG, Kapusta, M (2009). A comparative study of fast photomultipliers for timing experiments and TOF PET. *IEEE Trans Nucl Sci,* in press.

23) Szczęśniak T, Moszyński M, Świderki Ł, Nassalski A, Syntfeld-Każuch A, Ojala P, Bohm C (2009). A continuous crystal detector for TOF PET. *IEEE Nuclear Science Symposium and Medical Imaging Conference*, Dresden, Germany, October 2008, *IEEE Trans Nucl Sci,* submitted manuscript.

WP 2

24) Kramer G, Erdal H, Mertens H, Nap M, Mauerman J, Steiner G, Marberger M, Bivén K, Shoshan MC, Linder S (2004). Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. *Cancer Research* 64(5):751-1756.

25) Linder S, Havelka AM, Ueno T, Shoshan MC (2004). Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. *Cancer Lett* 214(1):1-9. Review.

26) Ueno T, Toi M, Linder S (2005). Detection of epithelial cell death in the body by cytokeratin 18 measurement. *Biomed Pharm* 59(Suppl. 2):S357-S360. Review.

27) Kramer G, Schwarz S, Hägg M, Mandic Havelka A and Linder S (2006). Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. *Br J Cancer* 94(11):1592-1598.

28) Ulukaya E, Yilmaztepe A, Akgoz S, Linder S and Karadag M (2007). The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. *Lung Cancer* 56(3):399-404.

29) Hägg Olofsson M, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, Muerdter T, Sonnenberg M, Aulitzky W, Schwarz S, Andersson E, Shoshan MC, Mandic Havelka A, Toi M and Linder S (2007). Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. *Clin Cancer Res* 13(11):3198-3206

30) Linder S (2007). Cytokeratin markers come of age. *Tumor Biol* 28:189-196.

31) Mandic Havelka A, Berndtsson M, Hägg Olofsson M, Shoshan MC, Linder S (2007). Mechanisms of action of DNA-damaging anticancer drugs in treatment of carcinomas: Is acute apoptosis an "Off-taget" effect? *Med Chem* 7:1035-1039. (Mini review).

32) Hägg Olofsson M, Cummings, J, Fayad, W., Brnjic, S., Herrmann, R., Berndtson, M., Hodginson, C., Dean, E., Busk, M., Dive, C. and Linder S (2008). Specific demonsration of drug-induced tumor cell apoptosis in human xenograts using a plasma biomarker. *Cancer Biomarkers*, 4:1-9. Galley proof (in press).

WP 3

33) Schütze S, Dörfler A, Eicheler W, Zips D, Hering S, Solca F, Baumann M, Krause M (2006). Combination of EGFR/HER2 Tyrosine Kinase Inhibition by BIBW 2992 and BIBW 2669 with Irradiation in FaDu Human Squamous Cell Carcinoma. *Strahlenther Onkol* 182(5):256–64.

34) Schütze C, Bergmann R, Yaromina A, Hessel F, Kotzerke J, Steinbach J, Baumann M, Beuthien-Baumann B (2007). Effect of radiation dose on local control correlates with pre-treatment [^{18}F]FDG uptake in FaDu tumours in nude mice. *Radiother Oncol* 83:311-315.

35) Christian N, Bol A, De Bast M, Labar D, Lee J, Mahy P, Grégoire V (2007). Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model. *Eur J Nucl Med Mol Imaging* 34(9):1348-54.

36) Zips D, Yaromina A, Schütze C, Wüllrich K, Krause M, Krause M, Hessel F, Eicheler W, Dörfler A, Brüchner K, Menegakis A, Zhou X, Bergmann R, van den Hoff J, Beuthien-Baumann B, Baumann M (2007). Experimental Evaluation of Functional Imaging for Radiotheraphy. *Strahlenther Onkol 2007* 183(Sondernr. 2):41-42.

37) Schütze C, Beuthien-Baumann B, Bergmann RHessel F, Kotzerke J, Baumann M (2007). Effekt der Bestrahlungsdosis auf die lokale Tumorkontrolle korreliert mit prätherapeutischer [18F]FDG-Aufnahme von FaDu-Tumoren in Nacktmäusen. *16. Symposium Experimentelle Strahlentherapie und Klinische Strahlenbiologie,* Dresden 01.-03. 03. 2007. *Dresden Proceedings* pp. 35-37.

38) Wüllrich K, Gabrys D, Hofheinz F, Brüchner K, Bergmann R, Krause M, Hessel F, Yaromina A, Eicheler W, Van den Hoff J, Baumann M, Beuthien-Baumann B (2007). Bewertung der FDG-Aufnahme in Abhängigkeit von Proliferation und Hypoxie: Untersuchung in 2 humanen Tumormodellen auf Nacktmäusen mit PET, Autoradiographie und funktioneller Histologie. *16. Symposium Experimentelle Strahlentherapie und Klinische Strahlenbiologie,* Dresden 01.-03. 03. 2007. *Dresden Proceedings* pp. 41-45.

39) Christian N, Lee JA, Bol A, De Bast M, Gallez B, Grégoire V (2008). Immobilization device for *in vivo* and *in vitro* multimodality image registration of rodent tumors. *Radiother Oncol* 87:147-51.

40) Christian N, Lee JA, Bol A, De Bast M, Jordan B, Grégoire V (2008). The limitation of PET imaging for biological adaptive-IMRT assessed in animal model *Radiother Oncol* Dec 19. [Epub ahead of print]

41) Richter S, Bergmann R, Pietzsch J, Beuthien-Baumann B, Wuest F (2008). Radiosynthesis of n.c.a. sodium [18F]fluoroacetate and radiopharmacological characterization in rats and tumour-xenografted mice. *Curr Radiopharm* 1: 103-109.

WP 4

42) Hultsch C, Pawelke B, Bergmann R, Wuest F (2006). Synthesis and evaluation of novel multimeric neurotensin(8-13) analogs. *Bioorg Med Chem* 14(17):5913-20.

43) Maes V, Hultsch C, Kohl S, Bergmann R, Hanke T, Tourwé D (2006). Fluorescein-labeled stable neurotensin derivatives. *J Pept Sci* 12(8):505-8.

44) Schlesinger J, Bergmann R, Klussmann S, Wuest, F (2006). Synthesis and radiopharmacological characterisation of 86Y- and 68Ga-labelled L-RNA oligonucleotides as molecular probes for positron emission tomography (PET). Letters in *Drug Design & Discovery* 3:330-335.

45) Kainz S, Czaja R, Greiner-Stöffele T, Hahn U (2006). Selection of RNase-resistant RNAs. *Handbook Exp Pharmacol* 173:447-55.

46) Haase C, Bergmann R, Oswald J, Zips D, Pietzsch J (2006). Neurotensin receptors in adeno- and squamous cell carcinoma. *Anticancer Res* 26:3527-3534.

47) Christian N, Bol A, De Bast M, Labar D, Lee JA, Mahy P, Grégoire V (2007). Determination of Tumor Hypoxia with the PET Tracer [^{18}F]EF3: Improvement of the tumor-to-background ratio in a mouse tumor model. *Eur J Nucl Med Mol Imaging* 34(9):1348-1354.

48) Wüllrich K, Gabrys D, Hofheinz F, Brüchner K, Bergmann R, Krause M, Hessel F, Yaromina A, Eicheler W, Van den Hoff J, Baumann M, Beuthien-Baumann B (2007). Bewertung der FDG-Aufnahme in Abhängigkeit von Proliferation und Hypoxie: Untersuchung in 2 humanen Tumormodellen auf Nacktmäusen mit PET, Autoradiographie und funktioneller Histologie. *16. Symposium Experimentelle Strahlentherapie und Klinische Strahlenbiologie, Dresden* 01.-03. 03. 2007, Dresden Proceedings p41-45.

49) Hultsch C, Berndt M, Bergmann R, Wuest F (2007). Radiolabeling of multimeric neurotensin(8-13) analogs with the short-lived positron emitter fluorine-18. *Appl Radiat Isotop* 65(7):818-26.

50) Schlesinger J, Koezle I, Bergmann R, Tamburini S, Bolzati C, Tisato F, Noll B, Klussmann S, Vonhoff S, Wuest F, Pietzsch HJ, Steinbach J (2008). An 86Y-labeled mirror-image oligonucleotide: Influence of Y-DOTA isomers on the biodistribu-tion in rats. *Bioconjug Chem* 19:928-939.

51) Werner A, Hahn U. FCS based characterisation of aptamer ligand interaction. In Mayer G. (Ed.): *Nucleic acids and peptide aptamers - Methods in Molecular Biology Series* Human Press Ltd., 2008 (in press).

52) Hahn U. Different contributions In Müller S. (Ed.): *Nucleic Acids from A to Z. A Concise Encyclopedia.* WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, 2008 (in press).

53) Werner A, Ziegelmüller P, Hahn U (2008). Ultrasensitive mobility based enzyme assay reveals a diffusion-controlled specificity constant of human Dicer in cell extracts, submitted to *Nucl Acids Res*.

54) Eydeler K, Magbanua E, Werner A, Ziegelmüller P, Hahn, U (2009). Fluorophore binding aptamers as a tool for RNA visualization. *Biophys J* 96 (9), in press.

55) Werner A, Konarev PV, Svergun DI, Hahn U (2009). Charaterization of a fluorophore binding RNA aptamer by fluorescence correlation spectroscopy and small angle X-ray scattering. *Anal Biochem,* Epub March 19.

WP 5

56) Troost EGC, Laverman P, Kaanders JHAM, Philippens M, Lok J, Oyen WJG, van der Kogel AJ, Boerman OC, Bussink J (2006). Imaging hypoxia after oxygenation-modification: comparing [^{18}F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. *Radiother Oncol* 80(2):157-64.

57) Eskola O, Grönroos T, Forsback S, Tuomela J, Haaparanta M, Bergman J, Minn H, Härkönen P, Solin O (2007). Electrophilic synthesis and pharmacokinetic properties of the hypoxia tracer [^{18}F]EF5 (submitted for publication 2007).

58) Grönroos T**,** Minn H (2007). Imaging of tumor hypoxia using PET and ^{18}F-labelled tracers: biology meets technology. *Eur J Nucl Med Mol Imaging* 34:1563-65.

59) Jordan BF, Christian N, Crokart N, Grégoire V, Feron O, Gallez B (2007). Thyroid status is a key modulator of tumor oxygenation: implication for radiation therapy. *Radiat Res* 168: 428-32.

60) Ljungkvist ASE, Bussink J, Kaanders JHAM, van der Kogel AJ (2007). Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers. *Radiat Res* 167:127-145. (Review)

61) Christian N, Bol A, De Bast M, Labar D, Lee J, Mahy P, Grégoire V (2007). Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model. *Eur J Nucl Med Mol Imaging* 34(9):1348-54.

62) Busk M, Horsman MR, Jakobsen S, Keiding S, van der Kogel AJ, Bussink J, and Overgaard J (2008). Imaging hypoxia in xenografted and murine tumors with ^{18}F-Fluoroazomycin Arabinoside: a comparative study involving microPET, autoradiography, pO_2-polarography and fluorescence microscopy. *Int J Radiat Oncol Biol Phys* 70:1202-12.

63) Busk M, Horsman MR, Kristjansen PEG, van der Kogel AJ, Bussink J, and Overgaard J (2008). Aerobic glycolysis in cancers: Implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. *Int J Cancer* 122:2726-2734.

64) Busk M, Horsman MR, Overgaard J (2008). Resolution in PET hypoxia imaging: Voxel size matters. *Acta Oncol* 47:1201-1210.

65) Minn H, Grönroos TJ, Komar G, Eskola O, Lehtiö K, Tuomela J, Sappänen M, Solin O (2008). Imaging of tumor hypoxia to predict treatment sensitivity. *Curr Pharm Design* 14(28):2932-2942.

66) Busk M, Horsman MR, Jakobsen S, van der Kogel AJ, Bussink J, and Overgaard J (2008). Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. *Eur J Nucl Med Mol Imaging* 35(12):2294-2303.

67) Mahy P, Geets X, Lonneux M, Levêque P, Christian N, De Bast M, Gillart J, Labar D, Lee J, Grégoire V (2008). Determination of tumor hypoxia with [^{18}F]EF3 in patients with head and neck tumors: a phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism. *Eur J Nucl Med Mol Imaging* 35:1282-1289.

68) Tuomela J, Grönroos T, Valta M, Seppänen J, Marjamäki P, Eskola O, Solin O, Minn H, Härkönen P (2008). Uptake of the hypoxia marker [^{18}F]EF5 in PC-3/VEGF and PC-3/FGF8b transfected tumors grown in nude mice (manuscript in preparation 2008).

69) Komar G, Seppänen M, Eskola O, Lindholm P, Grönroos S, Forsback S, Sipilä H, Evans SM, Solin O, Minn H (2008). [^{18}F]EF5: A new PET tracer for imaging hypoxia in head and neck cancer. *J Nucl Med* 49(12):1944-1951.

70) Komar G, Seppänen M, Hirvonen J, Vahlberg T, Bergman J, Teräs M, Minn H (2009). Comparison of 2D and 3D performance for [^{18}F]FDG PET with different acquisition times in oncological patients. *Nucl Med Comm* 30(1):16-24.

71) Mahy P, De Bast M, de Groot T, Cheguillaume A, Gillart J, Haustermans H, Labar D, Grégoire V (2009). Comparative pharmacokinetics, biodistribution, metabolism and hypoxia-dependent uptake of [^{18}F]-EF3 and [^{18}F]-MISO in rodent tumors model. Submitted to *Radiother Oncol* 89(3):353-360.

72) Christian N, Lee JA, Bol A, De Bast M, Jordan B, Grégoire V (2009). The limitation of PET imaging for biological adaptive-IMRT assessed in animal models. *Radiother Oncol* 91(1):101-106.

73) Dubois L, Landuyt W, Cloetens L, Bol A, Bormans G, Haustermans K, Labar D, Lambin P, Nuyts J, Vermaelen P, Grégoire V, Mortelmans L (2009). Evaluation of hypoxia in an experimental rat tumor model by 2-(2-nitroimidazol-1-yl)-N-(3[18F],3,3-trifluoropropyl)acetamide ([18F]EF3) PET imaging: a comparative study with [18F]fluoromisonidazole ([18F]FMISO). Submitted.

WP 6

74) Wells P, West C, Jones T, Harris A, Price P (2004). Measuring tumour pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine. *Biochem Biophys Acta* 1705:91-102.

75) Brock CS, Young H, Osman S, Luthra SK, Jones T, Price PM (2005). Glucose metabolism in brain tumours can be estimated using [^{18}F]2-fluorodeoxyglucose positron emission tomography and a population-derived input function scaled using a single arterialised venous blood sample. *Int J Oncol* 26(5):1377-83.

76) Wells P, Gunn RN, Steel C, Ranicar AS, Brady F, Osman S, Jones T, Price P (2005). 2-[(11)C]-thymidine positron emission tomography reproducibility studies in humans. *Clin Cancer Res* 11:4341-47.

77) Borst GR, Belderbos JS, Boellaard R, Comans EF, De Jaeger K, Lammertsma AA, Lebesque JV (2005). Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. *Eur J Cancer* 41:1533-41.

78) Laking GR, West C, Buckley DL, Matthews J, Price PM (2006). Imaging vascular physiology to monitor cancer treatment. *Crit Rev Oncol Haematol* 58(2):95-113.

79) Charnley N, West CM, Barnett CM, Brock C, Bydder GM, Glaser M, Newlands ES, Swindell R, Matthews J, Price P (2006). Early change in glucose metabolic rate

measured using FDG-PET in patients with high grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. *Int J Radiat Oncol Biol Phys* 66(22):331-8.

80) Gupta N, Saleem A, Kotz B, Osman S, Aboagye EO, Phillips R, Vernon C, Wasan H, Jones T, Hoskin PJ, Price PM (2006). Carbogen and nicotinamide increase blood flow and 5-fluorouracil (5-FU) delivery, but not 5-FU retention in colorectal cancer metastases in patients. *Clin Cancer Res* 12(10):3115-23.

81) Geets X, Daisne JF, Tomsej M, Duprez T, Lonneux M, Gregoire V (2006). Impact of the type of imaging modality on target volumes delineation and dose distribution in pharyngo-laryngeal squamous cell carcinoma: comparison between pre- and per-treatment studies. *Radiother Oncol* 78:291-297.

82) Saleem A, Charnley N and Price P (2006). Current perspectives in molecular imaging with PET. *Eur J Cancer* 42(12):1720-1727.

83) Janek S, Svensson R, Jonsson C, Brahme A (2006). Development of dose delivery verification by PET imaging of photonuclear reactions following high energy photon therapy. *Phys Med Biol* 51:5769-5783.

84) van Baardwijk A, Bosmans G, Dekker A, van Kroonenburgh M, Boersma L, Wanders S, Ollers M, Houben R, Minken A, Lambin P, de Ruysscher D (2007). Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. *Radiother Oncol* 82(2):145-52.

85) Troost EG, Vogel WV, Merkx MA, Slootweg PJ, Marres HA, Peeters WJ, Bussink J, van der Kogel AJ, Oyen WJ, Kaanders JH (2007). 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. *J Nucl Med* 48(5):726-35.

86) Geets X, Tomsej M, Lee JA, Duprez T, Coche E, Cosnard G, Lonneux M, Gregoire V (2007). Adaptive biological image-guided IMRT with anatomic and functional imaging in pharyngo-laryngeal tumours; impact on target volume delineation and dose distribution using helical tomopathy. *Radiother Oncol* 85(1):105-15.

87) Charnley N, Saleem A, Gupta N, Wells P, Anderson H, Harte R, West C, Swindell R, Bruce J, Jones T, Price P (2007). High blood flow and low volume of distribution of water measured using positron emission tomography in colorectal cancer metastases are associated with poor survival. Submitted to *Cancer Res*.

88) Price P (2007). The role of PET scanning in determining pharmacoselective doses in oncology drug development. *Ernst Schering Res Found Workshop* 2007:185-193.

89) van Baardwijk A, Bosmans G, Boersma L, Buijsen J, Wanders S, Hochstenbag M, van Suylen RJ, Dekker A, Dehing-Oberije C, Houben R, Bentzen SM, van Kroonenburgh M, Lambin P, de Ruysscher D (2007). PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumour and involved nodal volumes. *Int J Radiat Oncol Biol Phys* 68(3):771-8.

90) van Baardwijk A, Dooms C, van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C, Rupa D, Pastorekova S, Stroobants S, Buell U, Lambin P, Vansteenkiste J, de Ruysscher D (2007). The maximum uptake of (18)F-deoxyglucose on positron emission

tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small-cell lung cancer. *Eur J Cancer* 43(9):1392-8.

91) Geets X, Lee JA, Bol A, Lonneux M, Gregoire V (2007). A gradient-based method for segmenting FDG-PET images: methodology and validation. *Eur J Nucl Med Mol Imaging* 34(9):1427-38.

92) Gregoire V, Haustermans K, Geets X, Roels S, Lonneux M (2007). PET-based treatment planning in radiotherapy: a new standard? *J Nucl Med* 48 (Suppl 1):68S-77S.

93) Saleem A, Aboagye EO, Matthews JC, Price PM (2008). Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes. *Cancer Chemother Pharmacol* 61(5):865-73.

94) Rembielak A, Price P (2008). The role of PET in target localisation for radiotherapy planning. *Onkologie* 31:57-62.

95) Troost EGC, Laverman P, Philippens MEP, Lok J, van der Logel AJ, Oyen WJG, Boerman OC, Kaanders JHAM, Bussink J (2008). Correlation of [^{18}F]FMISO autoradiography and pimonidazole immunohistochemistry in human head and neck carcinoma xenografts. *Eur J Nucl Med Mol Imaging* 35(10):1803-11.

96) Castadot P, Lee JA, Parraga A, Geets X, Macq B, Gregoire V (2008). Comparison of 12 deformable registration strategies in adaptive radiation therapy for the treatment of head and neck tumours. *Radiother Oncol* 89(1):1-12.

97) Lee JA, Geets X, Gregoire V, Bol A (2008). Edge-preserving filtering of images with low photon counts. *IEEE Trans Pattern Anal Mach Intell* 30(6):1014-27.

98) Troost EGC, Laverman P, Kaanders JHAM, Oyen WJG, Boerman, OC, Bussink J (2008). Intratumoral spatial distribution of hypoxia and angiogenesis assessed by ^{18}F-FAZA and 1251-Gluco-RGD autoradiography – Letter to the Editor. *J Nucl Med* 49:1732.

99) Rembielak A, Cullen JN, Saleem A, Price P (2008). Imaging in cancer. *Medicine* 36(1):5-8.

100) Aerts HJ, Bosmans G, van Baardwijk AA, Dekker AL, Oellers MC, Lambin P, De Ruysscher D (2008). Stability of 18F-deoxyglucose uptake locations within tumour during radiotherapy for NSCLC: a prospective study. *Int J Radiat Oncol Biol Phys* 71(5):1402-7.

101) Öllers M, Bosmans G, van Baardwijk A, Dekker A, Lambin P, Teule J, Thimister W, Rhamy A, De Ruysscher D (2008). The integration of PET CT scans from different hospitals into radiotherapy treatment planning. *Radiother Oncol* 87(1):142-146.

102) van Loon J, Offermann C, Bosmans G, Wanders R, Dekker A, Borger J, Oellers M, Dingemans AM, van Baardwijk A, Teule J, Snoep G, Hochstenbag M, Houben R, Lambin P, De Ruysscher D (2008). 18FDG-PET based radiation planning of mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: a planning study. *Radiother Oncol* 87(1):49-54.

103) Janssen MH, Aerts HJ, Ollers MC, Bosmans G, Lee JA, Buijsen J, De Ruysscher D, Lambin P, Lammering G, Dekker AL (2009). Tumour delineation based on time-activity curve differences assessed with dynamic fluorodeoxyglucose positron emission tomography-computed tomography in rectal cancer patients. *Int J Radiat Oncol Biol Phys* 73(2):456-65.

104) Troost EGC, Bussink J, Oyen WJG, Kaanders HAM (2008). ^{18}F-FDG and ^{18}F-FLT do not discriminate between reactive and metastatic lymph nodes in oral cancer patients – Letter to the Editor *J Nucl Med* 50(3):490-491.

105) Koetz B, West C, Saleem A, Jones T, Price P (2009). Blood flow and V_d (water): both biomarkers required for interpreting the effects of vascular targeting agents on tumour and normal tissue. *Mol Cancer Ther* (In press).

WP 7

106) Geets X, Daisne J-F, Tomsej M, Duprez T, Lonneux M, Grégoire V (2006). Impact of the type of imaging modality on target volumes delineation and dose distribution in pharyngo-laryngeal squamous cell carcinoma: comparison between pre- and per-treatment studies. *Radiother Oncol* 78(3):291-297.

107) van Baardwijk A, Baumert BG, Bosmans G, van Kroonenburgh M, Stroobants S, Gregoire V, Lambin P, De Ruysscher D (2006). The current status of FDG–PET in tumour volume definition in radiotherapy treatment planning. *Cancer Treatment Rev* 32:245–260.

108) Gregoire V, Bol A, Geets X, Lee J (2006). Is PET-Based Treatment Planning the New Standard in Modern Radiotherapy? The Head and Neck Paradigm. *Semin Radiat Oncol* 16(4):232-238.

109) Bosmans G, van Baardwijk A, Öllers M, Boersma L, Minken A, Lambin P, De Ruysscher D (2006). Intra-patient variability of tumor volume and tumor motion during conventionally fractionated radiotherapy for locally advancd non-small lung cancer: A prospective clinical study. *Int J Radiat Oncol Biol Phys* 66(3):748–753.

110) Geets X, Tomsej M, Lee JA, Duprez T, Coche E, Cosnard G, Lonneux M, Grégoire V (2007). Adaptive biological image-guided IMRT with anatomic and functional imaging in pharyngo-laryngeal tumours: impact on target volume delineation and dose distribution using helical tomopathy. *Radiother Oncol,* 85(1):105-115.

111) Troost E, Vogel W, Merkx M, Slootweg PJ, Marres HAM, Peeters WJM, Bussink J, van der Kogel AJ, Oyen WJ, Kaanders JH (2007). 18F-FLT-PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. *J Nucl Med* 48(5):726-735.

112) van Baardwijk A, Dooms C, van Suylen R, Verbeken E, Hochstenbag M, Dehing-Oberije C, Rupa D, Pastorekova S, Stroobants S, Buell U, Lambin P, Vansteenkiste J, De Ruysscher D (2007). The maximum uptake of 18F-deoxyglucose on PET scan correlates with survival, Hypoxia Inducible Factor-1α and GLUT-1 in Non-Small Cell Lung Cancer. *Eur J Cancer* 43(9):1392-1398.

113) van Baardwijk A, Bosmans G, Boersma L, Buijsen J, Wanders S, Hochstenbag M, van Suylen RJ, Dekker A, Dehing-Oberije C, Houben R, Bentzen SM, van Kroonenburgh M, Lambin P, De Ruysscher D (2007). PET-CT-based auto-contouring in non-small-cell-lung cancer correlates with pathology and reduces inter-observer variability in the delineation of the primary tumor and involved nodal volumes. *Int J Radiat Oncol Biol Phys* 68(3):771-778.

114) van Baardwijk A, Bosmans G, Dekker A, van Kroonenburgh M, Boersma L, Wanders S, Öllers M, Minken A, Lambin P, De Ruysscher D (2007). Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally

advanced non-small cell lung cancer (NSCLC) patients. *Radiother Oncol* 82(2):145-152.

115) Lengelé B, Hamoir M, Scalliet P, Grégoire V (2007). Anatomical bases for the radiobiological delineation of lymph node areas. Major collecting trunks, head and neck. *Radiother Oncol* 85:146-155.

116) Haustermans K, Roels S, Verstraete J, Depuydt T, Slagmolen P (2007). Adaptive RT in rectal cancer: superior to 3D-CRT? A simple question, a complex answer. *Strahlenther Onkol* 183(Spec No 2):21-23.

117) Slagmolen P, Roels S, Loeckx D, Maes F, Haustermans K. (2007) Nonrigid registration of mesorectal region for PET signal follow-up during radiation therapy. AAPM Annual Meeting. *Med Phys* 34(6): 2326.

118) Geets X, Lee J, Bol A, Lonneux M, Grégoire V (2007). A gradient-based method for segmenting FDG-PET images: methodology and validation. *Eur J Nucl Med Mol Imag* 34(9):1427-1438.

119) Schinagl DAX, Vogel WV, Hoffmann AL, van Dalen JA, Oyen WJG, Kaanders JHAM (2007). Comparison of five segmentation tools for (18)F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer. *Int J Radiat Oncol Biol Phys* 69(4):1282-1289.

120) Bosmans G, van Baardwijk A, Dekker A, Öllers M, Wanders S, Boersma L, Lambin P, De Ruysscher D (2008). Time trends in nodal volumes and motion during radiotherapy for patients with stage III non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 71(1):139-144.

121) van Baardwijk A, Bosmans G, van Suylen RJ, van Kroonenburgh M, Hochstenbag M, Geskes G, Lambin P, De Ruysscher D (2008). Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: a feasibility study. *Radiother Oncol* 87(1):55-58.

122) Öllers G, Bosmans A, van Baardwijk A, Dekker A, Lambin P, Teule J, Thimister W, Rhamy A, De Ruysscher D (2008). The integration of PET-CT scans from different hospitals into radiotherapy treatment planning. *Radiother Oncol* 87(1):142-146.

123) Aerts HJ, Bosmans G, van Baardwijk AA, Dekker AL, Oellers MC, Lambin P, De Ruysscher D (2008). Stability of 18F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective study. *Int J Radiat Oncol Biol Phys* 71(5):1402-1407.

124) Roels S, Slagmolen P, Nuyts J, Lee JA, Loeckx D, Maes F, Stroobants S, Penninckx F, Haustermans K. (2008) Biological image-guided radiotherapy in rectal cancer: is there a role for FMISO or FLT, next to FDG? *Acta Oncol* 47(7):1237-48.

125) Castadot P, Lee JA, Parraga A, Geets X, Macq B, Grégoire V (2008). Comparison of 12 deformable registration strategies in adaptive radiation therapy for the treatment of head and neck tumors. *Radiother Oncol* 89(1):1-12.

126) Lee JA, Geets X, Grégoire V, Bol A (2008). Edge-preserving filtering of images with low photon counts. *IEEE Trans Pattern Anal Mach Intell* 30(6):1014-27.

127) Roels S, Slagmolen P, Nuyts J, Lee JA, Loeckx D, Maes F, Vandecaveye V, Stroobants S, Ectors N, Penninckx F, Karin Haustermans K (2009). Biological image-guided radiotherapy in rectal cancer: Challenges and pitfalls. *Int J Radiat Oncol Biol Phys* (*In Press)*. Epub ahead March 14.

128) Eisbruch A, Gregoire V (2009). Balancing risk and reward in target delineation for highly conformal radiotherapy in head and neck cancer. *Semin Radiat Oncol* 19(1):43-52.

WP 8

129) Cheng Q, Johansson L, Thorell J-O, Fredriksson A, Samén E, Stone-Elander S, Arnér ESJ (2006). Selenolthiol and dithiol C-terminal tetrapeptide motifs for one-step purification and labeling of recombinant proteins produced in E. coli. *Chem Biol Chem* 7(12):1976-1981.

130) Cheng Q, Stone-Elander S, Arnér ESJ (2006). Tagging recombinant proteins with a Sel-tag for purification, labeling with electrophilic compounds or radiolabeling with ^{11}C. *Nat Protoc* 1(2):604-613.

131) Thorell JO, Samén E, Stone-Elander S (2007). Synthesis and in vitro metabolism studies of the VEGFR2 inhibitor (R,S)N-(4-bromo-2-flourophenyl)-6-methoxy-7-[(1-[^{11}C]methyl-3-pieperidinyl)methoxy]-4-quinazolinamine. IRSC conference abstract, *J Lab Comp Radiopharm* 50(Suppl. 1):S323 (manuscript in preparation). [Abstract]

132) Stone-Elander SA, Fredriksson A (2007). 2-bromo-1-[^{18}F]fluoroethane – alternative purifica-tion procedure for wider solvent flexibility in subsequent alkylations. IRSC conference abstract, *J Lab Comp Radiopharm,* 50(Suppl 1):S158 (manuscript in preparation). [Abstract]

133) Prenant C, Gillies J, Bailey J, Chimon G, Smith N, Jayson GC, Zweit J (2008). Synthesis of [^{18}F]fluoroacetaldehyde. Application to [^{18}F]fluoroethylation of benzyl-amine under reductive alkylation conditions. *J Lab Comp Radiopharm* 51(6):262-267.

134) Samén E, Thorell JO, Lu L, Tegnebratt T, Holmgren L, Stone-Elander S (2009). Synthesis and preclinical evaluation of [^{11}C]PAQ as a PET imaging tracer for VEGFR-2. *Eur J Nucl Med Mol Imaging* Epub 14 March 2009.

WP 9

135) Brahme A, Gudowska I, Larsson S, Andreassen B, Holmberg R, Svensson R, Ivanchenko V, Bagukya A, Grichine V, Starkov N (2006). Application of GEANT4 in the development of new radiation therapy treatment mthods. In *Astroparticle, Particle and Space Physics, Detectors and Medical Physics Applications*, M. barone, E. Borchi, A. Gaddi, C. Leroy, L. Price, P.-G. Rancoita, R. Ruchti (Eds.). World Scientific, Singapore pp. 451-461.

136) Toma-Daşu I, Daşu A, Brahme A (2006). Influence of acute tumour hypoxia on radiation therapy outcome. AAPM Symposium Proceedings No. 14: Physical, Chemical and Biological Targeting in Radiation Oncology (editors: M Mehta, BR Paliwal and S Bentzen) pp. 111-117.

137) Qatarneh S (2006) Development of a Whole Body Atlas for Radiation Therapy Planning and Treatment Optimization. PhD Thesis, Stockholm, Sweden ISBN 91-7155-152-2.

138) Qatarneh SM, Kiricuta IC, Brahme A, Noz ME, Ferreira B, Kim WC, Lind BK (2007). Lymphatic atlas-based target volume definition for intensity-modulated radiation therapy planning. *Nucl Instr Meth Phys Res A* 580(2):1134–1139.

139) Brahme A (2009). Potential developments of light ion therapy: The ultimate conformal tretment modality; *1st NIRS International Open Laboratory Workshop on Innovation in the Radiation Therapy,* November 2008, Chiba, Japan. *Radiological Sciences* 52:8-31.

140) Brahme A, Nyman P, Skatt B (2009) 4D laser camera for accurate patient positioning, collision avoidance, image fusion and adaptive approaches during diagnostic and therapeutic procedures. [Manuscript]